Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A...

Area of Science:

• Rheumatology
• Drug Delivery Systems
• Biosimilars

Background:

• Rheumatoid arthritis (RA) impacts manual dexterity, making autoinjector ease-of-use critical for long-term therapy.
• Brenzys is an etanercept biosimilar developed to offer an alternative to Enbrel for RA treatment.

Purpose of the Study:

• To compare patient and healthcare professional preference and perceived ease of use of the Brenzys autoinjector against Enbrel MYCLIC (Australia) and Enbrel SureClick (Canada) autoinjectors.
• To evaluate the usability of a new autoinjector device for self-administration of RA therapy.

Main Methods:

• 191 RA patients and 90 healthcare professionals used Brenzys and Enbrel autoinjectors after training.
• Participants completed questionnaires assessing ease of use and preference after simulated injections.
• Study conducted in Australia and Canada with counterbalanced device order.

Main Results:

• Significantly more patients (79%) found the Brenzys autoinjector easier to use than Enbrel (p < 0.001).
• Healthcare professionals also rated Brenzys as significantly easier to use (86%) and recommended it over Enbrel (83%) (p < 0.001).
• Of patients with prior Enbrel autoinjector experience, 94% preferred switching to Brenzys.

Conclusions:

• The Brenzys autoinjector demonstrated statistically significant superiority in ease of use and preference among both RA patients and experienced healthcare professionals.
• Results suggest the Brenzys autoinjector may enhance self-delivery of etanercept therapy for rheumatoid arthritis.